← Back to Search

Inhibitor of Apoptosis Protein (IAP) antagonist

APG-1387 for Injection for Cancer

Phase 1

Waitlist Available

Research Sponsored by Ascentage Pharma Group Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18-24 months

Awards & highlights

Study Summary

This trial is testing the effects of a new drug, APG-1387, on patients with advanced solid tumors or lymphomas. So far, the drug has been well-tolerated in the patients tested. The goal of the trial is to further assess the antitumor effects of APG-1387 in combination with either pembrolizumab or a chemotherapeutic agent.

Eligible Conditions

Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18-24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18-24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18-24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum Tolerated Dose (MTD)

Secondary outcome measures

Anti-tumor effects of APG-1387 as a single agent

Anti-tumor effects of APG-1387 in combination with pembrolizumab or combination with paclitaxel and carboplatin in patients with advanced solid tumors

Pharmacokinetic evaluation

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: APG-1387 for InjectionExperimental Treatment1 Intervention

APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

APG-1387

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ascentage Pharma Group Inc.Lead Sponsor

46 Previous Clinical Trials

4,244 Total Patients Enrolled

Yifan Zhai, MD, PhDStudy ChairAscentage Pharma Group Inc.

18 Previous Clinical Trials

1,216 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have enrolled for this clinical experiment?

"Affirmative. According to the information on clinicaltrials.gov, this medical experiment is still actively looking for participants since its initial post date of November 21st 2017 and most recent update on August 12th 2022. Currently, 90 patients need to be enrolled across 3 separate locations."

Answered by AI

Is this investigation pioneering any new approaches?

"Since 2017, Ascentage Pharma Group Inc. has been researching APG-1387 for Injection and successfully earned Phase 1 drug approval after completing their first trial involving 90 patients in the same year. At present, 8 cities across 2 countries are hosting 4 active clinical trials on this medication."

Answered by AI

What adverse effects could arise from the ingestion of APG-1387?

"Although there is limited clinical evidence of efficacy and safety, our assessment of APG-1387 for Injection yielded a score of 1."

Answered by AI

Is this research initiative currently recruiting participants?

"Affirmative, there is evidence on clinicaltrials.gov that this medical trial has an ongoing search for suitable candidates. It was first announced in November 2017 and the most recent update to its information occurred on August 12th 2022. The study requires 90 enrollees over 3 sites."

Answered by AI

What additional research has been conducted to evaluate the efficacy of APG-1387 as an injectable treatment?

"In 2017, the University of Michigan conducted initial assessment on APG-1387 for Injection. This has since been followed by one completed study and four additional active investigations which are being carried out in Grand Rapids and Texas."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

2017. "APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03386526.